Six DLBCL cell lines of germinal center type harboring t(14;18)(p32;q21) and overexpressing BCL2 were used, including DoHH2, MCA and EJ, harboring a wt p53 gene, and Pfeiffer, MS and BJAB with mutated ...
Neuroblastoma, the most common extracranial solid tumor seen in children, is a cancer of the peripheral nervous system. The hallmark of neuroblastoma is variability in clinical outcome: Some tumors ...
This study was undertaken to investigate the role of mouse double minute 2 (MDM2) oncogene in prostate cancer growth and the potential of MDM2 as a target for prostate cancer therapy. An antisense ...
Proceedings of the National Academy of Sciences of the United States of America, Vol. 102, No. 3 (Jan. 18, 2005), pp. 731-736 (6 pages) The MYCN oncogene is the major negative prognostic marker in ...
Almost half of patients with advanced solid tumors or lymphomas experienced disease control with a drug that reactivates the TP53 tumor suppressor, a first-in-human study showed. Overall, the oral ...
TUCSON, Ariz., May 21, 2014 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced the launch of three new companion diagnostic robust prototype assays ...
A team of U.S. and South Korean researchers have developed an AI model called MSI-SEER that can not only predict microsatellite instability-high (MSI-H) tumors ...
Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial We analyzed a cohort ...
Biomarkers for Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced/Metastatic Breast Cancer: Translation to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback